Biostage, Inc. (BSTG)
Biostage, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Holliston, MA, US. The stock last traded at $4.03, up 0.75% on the session, giving a market capitalisation of $57.8M. On trailing twelve-month figures it carries a trailing P/E of -9.83, a net margin of 0.0%. Its beta of -0.97 implies it has historically moved less than the broad market.
Biostage, Inc. is a biotechnology enterprise dedicated to developing medical products aimed at curing patients suffering from cancers, injuries, and congenital defects within the gastrointestinal system and respiratory pathways. A primary focus for the company is the advancement of its Biostage Esophageal Implant, specifically designed to address esophageal cancer. Founded in 2009, the organization was formerly known as Harvard Apparatus Regenerative Technology, Inc. before rebranding as Biostage, Inc. in March 2016. Its corporate headquarters are located in Holliston, Massachusetts.
Biostage, Inc. is most often compared with the following Healthcare names: